See the published version of this preprint at BMC Pediatrics.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Xuming Mo
Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing 210008, China
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Backgroup: To study the effectiveness of thyroid hormones in predicting intensive care unit (ICU) mortality after cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD).
Methods: We retrospective observational analyzed data from 133 patients under 3 months old who underwent cardiac surgery with CPB from June 2017 to November 2019. ICU mortality prediction was assessed by multivariate binary logistic regression analysis and area under the curve (AUC) analysis.
Results: Non-survivors were younger (17.46±17.10 days vs. 38.63±26.87 days, P=0.006), with a higher proportion of neonates (9/13 vs. 41/120, P=0.017) and a higher proportion of individuals with Risk Adjustment in Congenital Heart Surgery-1 (RACHS-1) score ≥4 (8/13 vs. 31/120, P=0.020). No significant difference was found in CPB and aortic cross-clamping (ACC) time. The levels of free triiodothyronine (FT3) (3.91±0.99 pmol/L vs. 5.11±1.55 pmol/L, P=0.007) and total triiodothyronine (TT3) (1.55±0.35 nmol/L vs. 1.90±0.57 nmol/L, P=0.032) were higher in survivors compared with non-survivors. In the ICU mortality prediction assessment, only FT3 was an independent mortality predictor and showed a good AUC (0.856 ± 0.040).
Conclusion: FT3 was a powerful and the only independent predictor of ICU mortality in CHD infants under 3 months old after CPB.
Keywords
thyroid hormone, congenital heart disease, mortality
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Pediatrics.
Version 1
Posted 21 Sep, 2020
No community comments so far
Editorial decision: Major revision
On 09 Nov, 2020
Review #2 received
Received 07 Oct, 2020
Review #1 received
Received 23 Sep, 2020
Reviewer #1 agreed
On 22 Sep, 2020
Reviewer #2 agreed
On 22 Sep, 2020
Reviewers invited
Invitations sent on 22 Sep, 2020
Editor assigned
On 17 Sep, 2020
First submitted
On 16 Sep, 2020
Submission checks complete
On 16 Sep, 2020
Editor invited
On 16 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pediatrics
Learn more about our company.
See the published version of this preprint at BMC Pediatrics.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Xuming Mo
Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing 210008, China
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Pediatrics.
Version 1
Posted 21 Sep, 2020
No community comments so far
Editorial decision: Major revision
On 09 Nov, 2020
Review #2 received
Received 07 Oct, 2020
Review #1 received
Received 23 Sep, 2020
Reviewer #1 agreed
On 22 Sep, 2020
Reviewer #2 agreed
On 22 Sep, 2020
Reviewers invited
Invitations sent on 22 Sep, 2020
Editor assigned
On 17 Sep, 2020
First submitted
On 16 Sep, 2020
Submission checks complete
On 16 Sep, 2020
Editor invited
On 16 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pediatrics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Pediatrics.
Backgroup: To study the effectiveness of thyroid hormones in predicting intensive care unit (ICU) mortality after cardiopulmonary bypass (CPB) in infants with congenital heart disease (CHD).
Methods: We retrospective observational analyzed data from 133 patients under 3 months old who underwent cardiac surgery with CPB from June 2017 to November 2019. ICU mortality prediction was assessed by multivariate binary logistic regression analysis and area under the curve (AUC) analysis.
Results: Non-survivors were younger (17.46±17.10 days vs. 38.63±26.87 days, P=0.006), with a higher proportion of neonates (9/13 vs. 41/120, P=0.017) and a higher proportion of individuals with Risk Adjustment in Congenital Heart Surgery-1 (RACHS-1) score ≥4 (8/13 vs. 31/120, P=0.020). No significant difference was found in CPB and aortic cross-clamping (ACC) time. The levels of free triiodothyronine (FT3) (3.91±0.99 pmol/L vs. 5.11±1.55 pmol/L, P=0.007) and total triiodothyronine (TT3) (1.55±0.35 nmol/L vs. 1.90±0.57 nmol/L, P=0.032) were higher in survivors compared with non-survivors. In the ICU mortality prediction assessment, only FT3 was an independent mortality predictor and showed a good AUC (0.856 ± 0.040).
Conclusion: FT3 was a powerful and the only independent predictor of ICU mortality in CHD infants under 3 months old after CPB.
Figure 1
Loading...